Jade Biosciences advances JADE101 to Phase 3
Jade completed Q3 2026, initiating its Phase 3 EVERGREEN trial for JADE101. The company reported $476 million in cash, providing runway through Q4 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed